Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bob Kronemyer
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.
Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order
Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.
Start-Up Spotlight: Innovative Cardiovascular Solutions Hopes To Win Regulatory Nod For Embolic Protector For TAVR
Transcatheter aortic valve replacement (TAVR) is performed routinely using devices providing protection from stroke as standard of care. However, cerebral embolic protection devices currently available do not capture and remove emboli from all three vessels leading to the brain. The Emblok Embolic Protection System from Innovative Cardiovascular Solutions (ICS) has developed an embolic filter designed to protect all three cerebral vessels during TAVR and remove debris from the entire circulatory system.
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.